Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Primes Biosimilars Play Via South African Beachhead

Executive Summary

South Africa’s first biotech manufacturing facility is being set up by India's Cipla which hopes its strategy of "one global product standard at affordable pricing" could transform the biosimilars market. Some years ago, Cipla revolutionized treatment for HIV/AIDS with its less than a dollar a day treatment, though some analysts claim that it's still very early days to factor any disruptive impact that the firm could potentially have in the complex biosimilars segment.


Related Content

Cipla, Guojian launch first biosimilar Enbrel in India


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts